Specificity of antibody responses affected by extracorporeal immunoadsorption of plasma over columns of protein A silica.
A relationship is described between the interaction of circulating immune complexes (CIC) from plasma with staphylococcal protein A immunoadsorption treatment columns and modulation of antibody responses related to the specific CIC. Eluates from the initial immunoadsorption columns used to treat a series of patients with breast adenocarcinoma, cancer chemotherapy-associated thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (C-TTP/HUS), or immune thrombocytopenic purpura (ITP) were evaluated for disease-specific CIC containing Lex glycosphingolipid (Lex gl) adenocarcinoma-associated antigens or platelet autoantibody (anti-GPIIb/IIIa), together with the corresponding neutralizing antibody [anti-F(ab')2], and for nonspecific CIC containing cytomegalovirus (CMV) or herpes simplex virus type 1 (HSV-1) antigens. In addition, the levels of antibodies directed against CMV, HSV-1, Lex gl, and GPIIb/IIIa antigens, as well as anti-F(ab')2 antibodies, were compared in pretreatment and posttreatment serum samples. Columns used to treat breast adenocarcinoma patients contained only Lex gl CIC, and the only immunologic change observed after treatment was significant increases in anti-Lex gl antibodies in some patients. Columns used to treat C-TTP/HUS patients contained anti-GPIIb/IIIa-anti-F(ab')2 CIC, in addition to Lex gl CIC. After treatment, significant increases in anti-Lex gl and anti-F(ab')2 antibodies and significant decreases in anti-GPIIb/IIIa antibodies were observed in some patients. Columns used to treat ITP patients only exhibited anti-GPIIb/IIIa-anti-F(ab')2 CIC, and after treatment only decreases in anti-GPIIb/IIIa and increases in anti-F(ab')2 antibodies were observed in some patients.(ABSTRACT TRUNCATED AT 250 WORDS)
Snyder
H W
HW
IMRE Corporation, Seattle, WA 98109.
Seawell
B W
BW
Cochran
S K
SK
Balint
J P
JP
Jones
F R
FR
D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology / Q000628:therapy; D000912:Antibodies, Neoplasm / Q000276:immunology / Q000302:isolation & purification*; D000936:Antigen-Antibody Complex / Q000097:blood*; D000951:Antigens, Neoplasm / Q000276:immunology; D001323:Autoantibodies / Q000276:immunology / Q000302:isolation & purification*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology / Q000628:therapy; D006463:Hemolytic-Uremic Syndrome / Q000097:blood / Q000276:immunology / Q000628:therapy*; D006801:Humans; D007163:Immunosorbent Techniques; D007983:Lewis Blood Group Antigens / Q000276:immunology; D016553:Purpura, Thrombocytopenic, Idiopathic / Q000097:blood / Q000276:immunology / Q000628:therapy*; D012822:Silicon Dioxide; D013205:Staphylococcal Protein A
D000912:Antibodies, Neoplasm; D000936:Antigen-Antibody Complex; D000951:Antigens, Neoplasm; D001323:Autoantibodies; D007983:Lewis Blood Group Antigens; D013205:Staphylococcal Protein A; D012822:Silicon Dioxide